Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes

November 10, 2026 updated by: Sheraz Ali, Allied Hospital Faisalabad

Comparison of the Effect of Metformin-Sotagliflozin Versus Metformin-Empagliflozin Combination Therapy on Glycemic Control Measured by HbA1c in Patients With Type 2 Diabetes Mellitus

The goal of this randomized controlled trial is to compare two medicines added to metformin for blood sugar control in adults with type 2 diabetes whose HbA1c remains between 7.0% and 10.0% despite a stable dose of metformin. The main question it aims to answer is: Does adding sotagliflozin (a dual SGLT1/SGLT2 inhibitor) lower HbA1c more than adding empagliflozin (a selective SGLT2 inhibitor) after 24 weeks? Participants will continue their usual metformin dose and will be randomly assigned to take either sotagliflozin 200 mg or empagliflozin 10 mg once daily for 24 weeks. They will be reviewed at 4, 12 and 24 weeks for adherence, side effects and adverse events, and HbA1c will be measured at baseline and at 24 weeks.

Study Overview

Detailed Description

Pakistan has one of the highest adult diabetes prevalences in the world, and many patients fail to reach HbA1c targets on metformin monotherapy and require a second agent. SGLT2 inhibitors such as empagliflozin are established second-line agents. Sotagliflozin additionally inhibits intestinal SGLT1, blunting post-prandial glucose absorption and enhancing incretin release, which may provide additional glucose lowering. No head-to-head randomized comparison of these two combinations has been performed in Pakistan.

This is a single-centre, open-label, parallel-group randomized controlled trial with blinded outcome assessment, conducted at the Department of Medicine and Diabetic Clinic/Medicine OPD, Allied Hospital-I, Faisalabad Medical University. 140 patients (70 per group) will be enrolled by consecutive sampling and randomized 1:1. Sample size was calculated for 95% confidence, 80% power, SD of HbA1c change 1%, and a minimal clinically important difference of 0.5%, inflated by 10% for loss to follow-up. HbA1c will be measured by a standardized laboratory method at baseline and 24 weeks, with laboratory staff blinded to group allocation. Data will be analysed in SPSS; mean change in HbA1c will be compared using the independent-samples t-test (p ≤ 0.05 significant), with stratification for age, gender, BMI, duration of diabetes and baseline HbA1c.

Study Type

Interventional

Enrollment (Estimated)

140

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Punjab Province
      • Faisalabad, Punjab Province, Pakistan, 38000
        • Allied Hospital, Faisalabad Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 30 to 65 years, male or female
  • Diagnosed type 2 diabetes mellitus (ADA criteria)
  • Inadequately controlled on metformin: stable dose ≥1500 mg/day (or maximum tolerated dose) for at least 8 weeks, with HbA1c ≥7.0% and ≤10.0% at screening
  • Willing to provide written informed consent and attend scheduled follow-up

Exclusion Criteria:

  • Type 1 diabetes mellitus or secondary diabetes
  • Use of any SGLT inhibitor, GLP-1 receptor agonist, DPP-4 inhibitor or sulfonylurea within the previous 8 weeks
  • eGFR <45 mL/min/1.73 m², or significant hepatic impairment
  • Pregnancy, lactation, or women of childbearing potential not using contraception
  • Haemoglobinopathies
  • Known hypersensitivity to any study drug, or any condition making the patient unsuitable for the trial
  • Recurrent genital/urinary tract infections or history of Fournier's gangrene

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Metformin + Sotagliflozin (Group A)

Existing stable dose of metformin plus sotagliflozin 200 mg orally once daily for 24 weeks.

200 mg tablet orally once daily for 24 weeks

continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated)

Active Comparator: Metformin + Empagliflozin (Group B)

Existing stable dose of metformin plus empagliflozin 10 mg orally once daily for 24 weeks.

continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated)

10 mg tablet orally once daily for 24 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in HbA1c From Baseline to Week 24
Time Frame: Baseline and 24 weeks

Glycated haemoglobin (%) measured by a standardized laboratory method. Change calculated as baseline HbA1c minus week-24 HbA1c for each participant; a between-group difference ≥0.5% is considered clinically meaningful.

Baseline and 24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Adverse Events
Time Frame: Up to 24 weeks (assessed at weeks 4, 12 and 24)

Adverse events including genital/urinary tract infections, hypoglycaemia and gastrointestinal symptoms, recorded at follow-up visits.

Up to 24 weeks (assessed at weeks 4, 12 and 24)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sheraz Ali, Faisalabad Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

January 31, 2028

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared; aggregate results will be published in a peer-reviewed journal.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe